| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| SRTAStrata Critical Medical, Inc. | 494.88M | 5.73 | -16.37 | 10.44% | 17.65% | 14.27% | 0.04 |
| Sep 2019 | Sep 2020 | Sep 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 31.2M | 23.43M | 50.53M | 146.12M | 225.18M | 248.69M |
| Revenue Growth % | - | -0.25% | 1.16% | 1.89% | 0.54% | 0.1% |
| Cost of Goods Sold | 26.5M | 21.11M | 40.01M | 123.84M | 183.06M | 189.77M |
| COGS % of Revenue | 0.85% | 0.9% | 0.79% | 0.85% | 0.81% | 0.76% |
| Gross Profit | 4.7M | 2.33M | 10.52M | 22.27M | 42.12M | 58.92M |
| Gross Margin % | 0.15% | 0.1% | 0.21% | 0.15% | 0.19% | 0.24% |
| Gross Profit Growth % | - | -0.5% | 3.52% | 1.12% | 0.89% | 0.4% |
| Operating Expenses | 16.24M | 12.69M | 34.61M | 75.8M | 110.24M | 92.84M |
| OpEx % of Revenue | 0.52% | 0.54% | 0.69% | 0.52% | 0.49% | 0.37% |
| Selling, General & Admin | 15.49M | 11.82M | 32.93M | 70.26M | 105.61M | 89.66M |
| SG&A % of Revenue | 0.5% | 0.5% | 0.65% | 0.48% | 0.47% | 0.36% |
| Research & Development | 751K | 861K | 1.68M | 5.54M | 4.63M | 3.18M |
| R&D % of Revenue | 0.02% | 0.04% | 0.03% | 0.04% | 0.02% | 0.01% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -11.54M | -10.36M | -24.09M | -53.53M | -68.12M | -33.93M |
| Operating Margin % | -0.37% | -0.44% | -0.48% | -0.37% | -0.3% | -0.14% |
| Operating Income Growth % | - | 0.1% | -1.33% | -1.22% | -0.27% | 0.5% |
| EBITDA | -11.07M | -9.83M | -23.5M | -69.87M | -61.01M | -27.96M |
| EBITDA Margin % | -0.35% | -0.42% | -0.47% | -0.48% | -0.27% | -0.11% |
| EBITDA Growth % | - | 0.11% | -1.39% | -1.97% | 0.13% | 0.54% |
| D&A (Non-Cash Add-back) | 472K | 526K | 596K | -16.34M | 7.11M | 5.96M |
| EBIT | -11.54M | -10.36M | -24.09M | -53.53M | -68.12M | -33.93M |
| Net Interest Income | 703K | 199K | 460K | 3.43M | 8.44M | 7.21M |
| Interest Income | 703K | 200K | 460K | 3.43M | 8.44M | 7.21M |
| Interest Expense | 0 | 1K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 703K | 199K | -19.6M | 25.5M | 10.57M | 6.36M |
| Pretax Income | -10.84M | -10.16M | -43.7M | -28.03M | -57.54M | -27.56M |
| Pretax Margin % | -0.35% | -0.43% | -0.86% | -0.19% | -0.26% | -0.11% |
| Income Tax | 0 | 0 | -3.64M | -772K | -1.47M | -255K |
| Effective Tax Rate % | 1% | 1% | 0.92% | 0.97% | 0.97% | 0.99% |
| Net Income | -10.84M | -10.16M | -40.05M | -27.26M | -56.08M | -27.31M |
| Net Margin % | -0.35% | -0.43% | -0.79% | -0.19% | -0.25% | -0.11% |
| Net Income Growth % | - | 0.06% | -2.94% | 0.32% | -1.06% | 0.51% |
| Net Income (Continuing) | -10.84M | -10.16M | -40.05M | -27.26M | -56.08M | -27.31M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.47 | -0.81 | -0.57 | -0.38 | -0.76 | -0.35 |
| EPS Growth % | - | 0.45% | 0.3% | 0.33% | -1% | 0.54% |
| EPS (Basic) | -1.47 | -0.81 | -0.57 | -0.38 | -0.76 | -0.35 |
| Diluted Shares Outstanding | 7.36M | 12.51M | 70.1M | 71.24M | 73.52M | 77.5M |
| Basic Shares Outstanding | 7.36M | 12.51M | 70.1M | 71.24M | 73.52M | 77.5M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Sep 2019 | Sep 2020 | Sep 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 1.43M | 14.38M | 294.94M | 218.13M | 206.26M | 160.74M |
| Cash & Short-Term Investments | 277.57M | 12.16M | 281.97M | 192.08M | 166.14M | 127.14M |
| Cash Only | 1.31M | 12.16M | 2.6M | 41.34M | 27.87M | 18.38M |
| Short-Term Investments | 276.26M | 0 | 279.37M | 150.74M | 138.26M | 108.76M |
| Accounts Receivable | 0 | 1.09M | 5.55M | 10.88M | 21M | 21.59M |
| Days Sales Outstanding | - | 17.01 | 40.08 | 27.17 | 34.05 | 31.69 |
| Inventory | 0 | 512K | 547K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | 8.85 | 4.99 | - | - | - |
| Other Current Assets | -276.14M | 114K | 83K | 3.08M | 19.12M | 12.02M |
| Total Non-Current Assets | 276.26M | 3.34M | 40.94M | 106.9M | 88.68M | 95.93M |
| Property, Plant & Equipment | 0 | 2.5M | 2.76M | 19.73M | 26.38M | 39.79M |
| Fixed Asset Turnover | - | 9.39x | 18.32x | 7.41x | 8.54x | 6.25x |
| Goodwill | 0 | 0 | 13.33M | 39.45M | 40.37M | 41.05M |
| Intangible Assets | 0 | 533K | 24.42M | 46.37M | 20.52M | 13.65M |
| Long-Term Investments | 276.26M | 200K | 200K | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 107K | 232K | 1.36M | 1.4M | 1.44M |
| Total Assets | 277.69M | 17.71M | 335.88M | 325.02M | 294.94M | 256.68M |
| Asset Turnover | 0.11x | 1.32x | 0.15x | 0.45x | 0.76x | 0.97x |
| Asset Growth % | - | -0.94% | 17.96% | -0.03% | -0.09% | -0.13% |
| Total Current Liabilities | 371.31K | 6.34M | 12.78M | 26.61M | 35.49M | 22.73M |
| Accounts Payable | 0 | 776K | 6.37M | 16.54M | 0 | 0 |
| Days Payables Outstanding | - | 13.42 | 58.11 | 48.74 | - | - |
| Short-Term Debt | 231.37K | 1.17M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 1000K | 1000K |
| Other Current Liabilities | 139.94K | 3.97M | 5.98M | 6.71M | 23.86M | 12.77M |
| Current Ratio | 3.85x | 2.27x | 23.07x | 8.20x | 5.81x | 7.07x |
| Quick Ratio | 3.85x | 2.19x | 23.03x | 8.20x | 5.81x | 7.07x |
| Cash Conversion Cycle | - | 12.44 | -13.04 | - | - | - |
| Total Non-Current Liabilities | 231.37K | 291K | 31.73M | 23.93M | 25.15M | 12.01M |
| Long-Term Debt | 231.37K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 291K | 278K | 14.97M | 19.74M | 6.02M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 451K | 185K |
| Other Non-Current Liabilities | 0 | 0 | 31.45M | 8.96M | 4.96M | 5.81M |
| Total Liabilities | 272.69M | 6.63M | 44.51M | 50.54M | 60.64M | 34.74M |
| Total Debt | 462.73K | 1.89M | 716K | 18.33M | 24.52M | 9.32M |
| Net Debt | -842.88K | -10.28M | -1.88M | -23.01M | -3.35M | -9.06M |
| Debt / Equity | 0.09x | 0.17x | 0.00x | 0.07x | 0.10x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | - | -10359.00x | - | - | - | - |
| Total Equity | 5M | 11.08M | 291.37M | 274.49M | 234.3M | 221.94M |
| Equity Growth % | - | 1.22% | 25.3% | -0.06% | -0.15% | -0.05% |
| Book Value per Share | 0.68 | 0.89 | 4.16 | 3.85 | 3.19 | 2.86 |
| Total Shareholders' Equity | 5M | 11.08M | 291.37M | 274.49M | 234.3M | 221.94M |
| Common Stock | 132 | 3K | 7K | 7K | 7K | 7K |
| Retained Earnings | 784.78K | -37.14M | -76.42M | -103.68M | -159.75M | -186.9M |
| Treasury Stock | - | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -898K | 2.29M | 3.96M | 1.75M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Sep 2019 | Sep 2020 | Sep 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -10.3M | -10.82M | -15.62M | -37.13M | -32.35M | -2.52M |
| Operating CF Margin % | -0.33% | -0.46% | -0.31% | -0.25% | -0.14% | -0.01% |
| Operating CF Growth % | - | -0.05% | -0.44% | -1.38% | 0.13% | 0.92% |
| Net Income | -10.84M | -10.16M | -40.05M | -27.26M | -56.08M | -27.31M |
| Depreciation & Amortization | 472K | 526K | 596K | 5.72M | 7.11M | 5.96M |
| Stock-Based Compensation | 317K | 490K | 9.62M | 0 | 12.5M | 19.89M |
| Deferred Taxes | 0 | 0 | -3.64M | -772K | -1.47M | -255K |
| Other Non-Cash Items | 28K | 0 | 20.06M | -14.81M | 12.32M | 2.2M |
| Working Capital Changes | -281K | -1.67M | -2.2M | -17K | -6.74M | -3.01M |
| Change in Receivables | -165K | -591K | -414K | -5.35M | -10.25M | -998K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 9.9M | 0 | 0 |
| Cash from Investing | -1.05M | -377K | -321.34M | 79.34M | 17.09M | -1.02M |
| Capital Expenditures | -604K | -377K | -297K | -730K | -2.11M | -30.88M |
| CapEx % of Revenue | 0.02% | 0.02% | 0.01% | 0% | 0.01% | 0.12% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | -250K | 0 | -504K | 0 | 138K | -2.11M |
| Cash from Financing | 116K | 1.18M | 332.26M | -1.08M | -76K | -5.76M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 116K | 15K | 213.79M | -1.17M | -76K | -5.51M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -11.16M | -11.2M | -16.42M | -37.86M | -34.46M | -35.51M |
| FCF Margin % | -0.36% | -0.48% | -0.32% | -0.26% | -0.15% | -0.14% |
| FCF Growth % | - | -0% | -0.47% | -1.31% | 0.09% | -0.03% |
| FCF per Share | -1.52 | -0.89 | -0.23 | -0.53 | -0.47 | -0.46 |
| FCF Conversion (FCF/Net Income) | 0.95x | 1.06x | 0.39x | 1.36x | 0.58x | 0.09x |
| Interest Paid | - | 0 | 12K | 0 | 0 | 0 |
| Taxes Paid | - | 0 | 0 | 0 | 16K | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -216.76% | -126.37% | -26.48% | -9.63% | -22.04% | -11.97% |
| Return on Invested Capital (ROIC) | - | -313.2% | -12.45% | -14.84% | -21.18% | -11.47% |
| Gross Margin | 15.06% | 9.93% | 20.82% | 15.24% | 18.71% | 23.69% |
| Net Margin | -34.74% | -43.36% | -79.27% | -18.66% | -24.9% | -10.98% |
| Debt / Equity | 0.09x | 0.17x | 0.00x | 0.07x | 0.10x | 0.04x |
| Interest Coverage | - | -10359.00x | - | - | - | - |
| FCF Conversion | 0.95x | 1.06x | 0.39x | 1.36x | 0.58x | 0.09x |
| Revenue Growth | - | -24.88% | 115.61% | 189.2% | 54.11% | 10.44% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Medical | - | 71.78M | 126.6M | 146.82M |
| Medical Growth | - | - | 76.38% | 15.97% |
| Passenger | - | 74.34M | 98.58M | 101.88M |
| Passenger Growth | - | - | 32.60% | 3.35% |
| MediMobility Organ Transport And Jet | 26.35M | - | - | - |
| MediMobility Organ Transport And Jet Growth | - | - | - | - |
| Short Distance | 22.25M | - | - | - |
| Short Distance Growth | - | - | - | - |
| Other | 1.93M | - | - | - |
| Other Growth | - | - | - | - |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| UNITED STATES | - | 133.3M | 190.74M | 218.75M |
| UNITED STATES Growth | - | - | 43.10% | 14.68% |
| Non-US | - | 12.82M | 34.44M | 29.95M |
| Non-US Growth | - | - | 168.57% | -13.04% |
Strata Critical Medical, Inc. (SRTA) reported $228.8M in revenue for fiscal year 2024. This represents a 633% increase from $31.2M in 2019.
Strata Critical Medical, Inc. (SRTA) grew revenue by 10.4% over the past year. This is steady growth.
Yes, Strata Critical Medical, Inc. (SRTA) is profitable, generating $40.4M in net income for fiscal year 2024 (-11.0% net margin).
Strata Critical Medical, Inc. (SRTA) has a return on equity (ROE) of -12.0%. Negative ROE indicates the company is unprofitable.
Strata Critical Medical, Inc. (SRTA) had negative free cash flow of $54.6M in fiscal year 2024, likely due to heavy capital investments.